Deep science startup Iom Bioworks has raised ₹4 crore in a seed funding round led by Inflection Point Ventures (IPV), with the capital set to bolster marketing, intellectual property (IP) protection, infrastructure and team expansion.
The Bengaluru-based firm, which focuses on leveraging gut microbiome science for personalised healthcare, aims to scale its operations following a strong first-year performance, said a statement.
Founded in 2022, Iom Bioworks uses artificial intelligence (AI) and computational biology to analyse and modulate gut bacteria, offering tailored health recommendations. The company claims its patented platform combines AI-driven data mining with advanced modelling to deliver precise wellness solutions.
In its first year of operations, the startup says it onboarded over 500 users, secured two global patents and has two more in progress. The company has also published research in leading scientific journals and established pan-India logistics for its microbiome-based services.
Bipin Pradeep Kumar, Co-Founder and CEO, Iom Bioworks, said, “Iom Bioworks envisions a world where a healthy mind and body are achievable through informed choices that nurture the microbiome. By empowering our inner ecosystem through prebiotics and a food and lifestyle centred around the bacteria, we aim to energise daily life while preserving the joy of living. Partnering with IPV has been transformative; their supportive and diligent approach has set us firmly on the path toward this vision.”
The company’s leadership team includes Dr. Samik Ghosh, Co-Founder and Chief of Science & Technology, who specialises in computational biology, and Dr. Hiroaki Kitano, Co-Founder and Chief of Research & Collaboration, a systems biology and AI expert.
The global market for health tests, wellness subscriptions, and digital health platforms is projected to reach $900 billion by 2030, growing at a 28% compound annual growth rate (CAGR). Iom Bioworks says its science-backed, scalable approach positions it to capitalise on the expanding demand for personalised gut health solutions.
IPV, the lead investor in this round, has deployed over ₹800 crore across 210 startups to date. The venture firm’s backing underscores growing investor interest in microbiome-based healthcare innovations.
IPV founder Vinay Bansal, said, “Lifestyle diseases have been on the rise due to multiple reasons like poor diet, stress, lack of sleep and are intimately linked to poor gut health and microbial composition. The gut microbiome plays a huge role in your digestion, immunity, metabolism, and even mood. Understanding it can help prevent a myriad of these diseases and also provide a better quality of life. Iom Bioworks is making this cutting-edge science accessible, personalised and importantly, actionable.”
